US-based biopharmaceutical company Regado Biosciences secures $51m in Series E funding from investors including RusnanoMedInvest and Baxter Ventures, a corporate venturing unit of Baxter Healthcare.
RusnanoMedInvest, a subsidiary of the state-run Russian investment firm Rusnano, has led a $51m Series E round into Regado Biosciences, a thrombosis treatment company.
There was also participation from new investor Baxter Healthcare’s venture initiative, Baxter Ventures. Existing investors private equity firm Edmond de Rothschild Investment Partners and venture capital firms Domain Associates, Quaker Partners, Aurora Funds and Caxton Advantage Life Sciences Fund were also involved.
David J. Mazzo, President and Chief Executive of Regado, said: “We welcome new investors…
